Parag Sevak, MD
Radiation Oncology · Louisville, KYNPI 1558705210
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $232 and has fallen 80.2% since, to $46 in 2024. That places this record below the midpoint for radiation oncology clinicians in KY, where the typical reported total is $669.
Across 26 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$66
- E.r. Squibb & Sons, L.L.C.$60
- Merck$38
- Bayer$38
- Sanofi$32
- Clovis Oncology, Inc.$29
- plus $196 from 11 others
Across 127 payments — averaging $179.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GT Medical Technologies, Inc$23K
What the payments were for
- Food & beverage$460100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 3 | $66 |
| E.r. Squibb & Sons, L.L.C. | 2 | $60 |
| Merck | 3 | $38 |
| Bayer | 2 | $38 |
| Sanofi | 2 | $32 |
| Clovis Oncology, Inc. | 2 | $29 |
| Lilly USA, LLC | 2 | $27 |
| Monteris Medical Corporation | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Novartis | 1 | $19 |
| Amgen | 1 | $18 |
| Advanced Accelerator Applications | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $12 |
| Verastem, Inc. | 1 | $12 |
How this compares
$460 in reported general payments places this provider in the 35th percentile of 81 radiation oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 28 | $633 |
| Dexamethasone | 39 | $354 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $111 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Louisville
- Neal DunlapLouisville$98K
- Craig SilvermanLouisville$9K
- Shiao WooLouisville$7K
- Justin AndersonLouisville$5K
- Aaron SpaldingLouisville$5K
- Yong ChaLouisville$4K
- Adrianna MastersLouisville$4K
- Alden KlarerLouisville$3K
- Carole ScharfLouisville$2K
- Phylicia OdumeLouisville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.